BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yasuoka H. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:97-110. [PMID: 26819563 DOI: 10.4137/CCRPM.S23315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Park HJ, Jeong OY, Chun SH, Cheon YH, Kim M, Kim S, Lee SI. Butyrate Improves Skin/Lung Fibrosis and Intestinal Dysbiosis in Bleomycin-Induced Mouse Models. Int J Mol Sci 2021;22:2765. [PMID: 33803282 DOI: 10.3390/ijms22052765] [Reference Citation Analysis]
2 Butt SA, Jeppesen JL, Fuchs C, Mogensen M, Engelhart M, Torp-Pedersen C, Gislason GH, Jacobsen S, Andersson C. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatol 2018;2:36. [PMID: 30886986 DOI: 10.1186/s41927-018-0043-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Jung E, Suh CH, Kim HA, Jung JY. Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease. Arch Rheumatol 2018;33:322-7. [PMID: 30632529 DOI: 10.5606/ArchRheumatol.2018.6630] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Chowaniec M, Skoczyńska M, Sokolik R, Wiland P. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia 2018;56:249-54. [PMID: 30237630 DOI: 10.5114/reum.2018.77977] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, Nitskovich R, Szymańska E, Walecka I. Systemic sclerosis - multidisciplinary disease: clinical features and treatment. Reumatologia 2019;57:221-33. [PMID: 31548749 DOI: 10.5114/reum.2019.87619] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
6 Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 2019;58:567-79. [PMID: 29893938 DOI: 10.1093/rheumatology/key151] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
7 Nili M, Singer D, Hanna M. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype. BMC Pulm Med 2022;22:153. [PMID: 35459138 DOI: 10.1186/s12890-022-01953-9] [Reference Citation Analysis]
8 Mori S, Furukawa H, Kawaguchi Y, Suda T, Tasaka S. Current Developments in Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med 2015;9:173-7. [PMID: 27656093 DOI: 10.4137/CCRPM.S40867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Dowson C, Simpson N, Duffy L, O'Reilly S. Innate Immunity in Systemic Sclerosis. Curr Rheumatol Rep 2017;19:2. [PMID: 28116578 DOI: 10.1007/s11926-017-0630-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
10 Bolourani S, Sari E, Brenner M, Wang P. The role of eCIRP in bleomycin-induced pulmonary fibrosis in mice. PLoS One 2022;17:e0266163. [PMID: 35377906 DOI: 10.1371/journal.pone.0266163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]